In line with these data, we recently reported that a STAT5 inhibitor associated with IM suppresses the growth of IM‐resistant CML cells by blocking STAT5B protein expression.41 This evidence concerns the gene STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive.